VA-MARS,-INCORPORATED
3.5.2024 15:01:32 CEST | Business Wire | Press release
Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland. With approximately 140 Associates, Cerba Vet provides full animal-related service diagnostics with complete clinical and anatomic pathology testing as well as endocrinology, microbiology, serology, hematology, chemistry, and other advanced tests, to veterinary practitioners. Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually.
Headquartered in Lyon, France, ANTAGENE is a leading player in animal genetics in Europe, recognised for its expertise in DNA testing for dogs, cats, horses and wildlife. ANTAGENE offers tests globally for diagnosing diseases in pets, as well as supporting scientific initiatives to preserve biodiversity.
Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world.
Nefertiti Greene, President, Mars Science & Diagnostics, said: “We are excited about this opportunity and look forward to finalizing discussions and working together with the Cerba Vet and ANTAGENE teams to enhance our reach and drive R&D to help veterinarians improve animal health outcomes, delivering A BETTER WORLD FOR PETS™.”
Emmanuel Ligner, CEO, Cerba HealthCare, added: “We are proud of what the teams have accomplished over the years to lead innovation and enhance services for the entire veterinarian community. We believe that Mars Science & Diagnostics is the right investor for Cerba Vet and ANTAGENE and would be able to support the long-term development and growth of these businesses. Mars Science & Diagnostics is known for its commitment to science and innovation, strong partnerships with veterinary professionals and purpose-driven culture.”
The contemplated acquisition remains subject to the information and/or consultation of the employees and employee representative bodies of Cerba Vet and ANTAGENE. Completion of such contemplated acquisition would also be subject to customary closing requirements following the execution of definitive transaction agreements.
About Mars, Incorporated
For more than a century, Mars, Incorporated has been driven by the belief that the world we want tomorrow starts with how we do business today. This common purpose unites our 140,000+ Associates. It is at the center of who we are as a global, family-owned business, and it fuels how we are transforming, innovating, and evolving to make a positive impact on the world.
Every year, our diverse and expanding portfolio of quality confectionery, food, and pet care products and services delights millions of people and supports millions of pets. With more than $47 billion in annual sales, we produce some of the world’s best-loved brands including CESAR®, Ben’s Original™, PEDIGREE®, ROYAL CANIN®, Cocoavia®, DOVE®, EXTRA®, KIND®, M&M’s®, SNICKERS® and WHISKAS®. We are creating a better world for pets through nutrition, breakthrough programs in diagnostics, wearable health monitoring, DNA testing, pet welfare and comprehensive veterinary care with AniCura, BANFIELD™, BLUEPEARL™, Linnaeus and VCA™. Mars Science & Diagnostics is a division of Mars Petcare dedicated to one purpose: A BETTER WORLD FOR PETS. Science & Diagnostics brings together the power of leading science with expertise across diagnostics, data, and technology to change outcomes in pet health.
We know we can only be truly successful if our partners and the communities in which we operate prosper as well. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire our Associates to take action every day to help create a world tomorrow in which the planet, its people and pets can thrive.
For more information about Mars, please visit www.mars.com. Join us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
About Mars Science & Diagnostics
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business Antech spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90 reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503904264/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digital Trust Index 2026: AI Skepticism and Identity Access Friction Are Costing Revenue31.3.2026 14:00:00 CEST | Press release
93% of IT leaders are deploying GenAI, but only 23% of consumers trust companies that use AI to handle their data. Friction at sign-up, login, and onboarding is causing customer abandonment and revenue loss, with 68% of consumers switching due to website issues. 69% of consumers trust companies more when MFA (multi factor authentication) is used, 68% say the same about passkeys. Thales today released the 2026 Digital Trust Index, one of the most comprehensive global studies of digital trust. Surveying more than 15,000 consumers, business partners, and IT decision makers across 13 industries, the research reveals that digital trust is won or lost during sign-up, login, and throughout the lifecycle of personal data handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331668723/en/ Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. ©Thales Consumer Trust is Won or Lost at Login
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients31.3.2026 14:00:00 CEST | Press release
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program. FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care. eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa
SLB and Azule Energy Scale Enterprise Digital Operations to Strengthen Energy Delivery in Angola31.3.2026 14:00:00 CEST | Press release
SLB’s enterprise digital platform will enhance execution reliability across Azule’s operations in Angola Global technology company SLB (NYSE: SLB) today announced a three-year agreement with Azule Energy to continue and expand the use of its enterprise digital platform across Azule’s operations in Angola. The platform will help Azule drive more consistent execution, accelerate decision-making, and support reliable energy delivery across its portfolio. Azule Energy — a joint venture of bp and Eni and the largest independent energy producer in Angola — operates some of the region’s most complex assets. The agreement builds on two years of Delfi™ use within Azule’s reservoir organization, where the platform supports reservoir studies, modelling, simulation, and well planning workflows, and supports enterprise-scale digital integration by connecting reservoir workflows with broader operational data environments over time. “Azule operates large, complex energy assets where execution reliabi
Esri and RoboGarden Sign Strategic MOU to Advance Geospatial and Geomatics Education31.3.2026 14:00:00 CEST | Press release
Agreement Explores New Models for Digital Learning, Academic Collaboration, and Global Workforce Readiness Esri and RoboGarden have signed an MOU to explore strategic collaboration that broadens access to modern GIS and geomatics education. RoboGarden, a Canadian EdTech company, offers gamified and scalable digital learning solutions for academic institutions, governments, and industry. The MOU outlines joint exploration of academic pathways, improved regional coordination, and potential creation of a Geospatial & Geomatics Virtual Academy. The agreement focuses on enhancing digital learning delivery, expanding localized e-learning opportunities, and supporting global workforce development in high-demand technology fields. To stay informed about Esri’s education initiatives and resources, visit esri.com/en-us/industries/education/overview. Esri, the global leader in geographic information system (GIS) technology, today announced the signing of a Memorandum of Understanding (MOU) with R
ExaGrid Named a Finalist for the Network Computing Awards 202631.3.2026 14:00:00 CEST | Press release
ExaGrid nominated in 11 Categories for annual industry awards ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 11 categories for the annual Network Computing Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331887370/en/ ExaGrid has become a finalist in the following categories: Data Protection Product of the Year The Return On Investment Award Air Gapped Ransomware Recovery Product of the Year Storage Product of the Year Hardware Product of the Year The Customer Service Award Enterprise Product of the Year New Product of the Year Product of the Year Company of the Year Additionally, ExaGrid is nominated for the “Bench Tested Product of the Year” award determined by judges after an independent product review of the ExaGrid Tiered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom